Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Various studies have pointed toward GLP-1 RAs causing mental health complications, such as anxiety and depression. The National Institutes of Health (NIH) published research in June 2024 that ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Two in three adults over the age of 25 could be obese or overweight by 2050, experts have warned. Access to healthy and ...

Weight loss can reverse the cardiovascular changes that take place in the heart, but will a new diet and exercise work, or is ...

A qualitative study reveals that providers mostly avoid stigmatizing terms but would welcome additional guidance on ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

According to recent reporting, Gov. Josh Shapiro is considering cutting off access to the weight loss drugs like Zepbound and Wegovy to all Medicaid recipients in the state who are not dangerously ...

A common diabetes drug can be repurposed to help overweight and obese people with knee arthritis ... but it is a major problem because patient dissatisfaction with knee replacements is already ...

More than 2.5 billion adults worldwide are overweight or obese. Many develop type 2 diabetes (T2D) and other complications. Bariatric surgery is an effective treatment option for significantly ...